13D Filing: Farallon Capital and Nexvet Biopharma PLC (NVET)

Page 32 of 68

Page 32 of 68 – SEC Filing

relationships (legal or otherwise) among the Reporting Persons or between such persons and any other person with respect to any securities of the Company, including but not limited to the transfer or voting of any securities of the Company, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, divisions of profits or loss, or the giving or withholding of proxies.
Item 7. Materials to be Filed as Exhibits
Item 7 is supplemented to report the following:
There is filed herewith as Exhibit 6 a written agreement relating to the filing of joint acquisition statements as required by Section 240.13d-1(k) under the Securities Exchange Act of 1934, as amended.
The respective Farallon Deeds are filed herewith as Exhibits 7, 8 and 9.
The Patel Deed is filed herewith as Exhibit 10.

Follow Nexvet Biopharma Plc (NASDAQ:NVET)

Page 32 of 68